{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:40Z","timestamp":1793915680064,"version":"4.8.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We investigated whether the acetylcholine receptor (AChR) cluster cell-based assay (CBA) is effective in detecting AChR antibodies in sera from myasthenia gravis (MG) patients with low antibody concentrations, as determined by radioimmunoprecipitation assay (RIPA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective diagnostic cohort study, 193 RIPA-positive sera from MG patients were analyzed. Following initial assessment using the gold-standard RIPA, samples were tested with a commercially available fixed CBA (F-CBA) and an in-house live CBA (L-CBA) to detect clustered AChR antibodies. Patients were classified into three groups based on RIPA levels to evaluate the sensitivity of each CBA. A subset of the cohort was blindly retested in a second laboratory to confirm results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The sensitivity of L-CBA and F-CBA in detecting 36 sera with low AChR-antibody levels (1.0\u20132.8 nM) was relatively high for L-CBA (83.33%, 95% CI: 71.16%, 95.51%) and low for F-CBA (45.71%, 95% CI: 29.21% to 62.22%). Both CBAs were 100% sensitive for sera with AChR-RIPA values &amp;gt; 3 nM. Antibodies of RIPA+\/CBA\u2212 sera could be immunoadsorbed on AChR-transfected cells equally well as those from RIPA+\/CBA+ sera, indicating that CBA negativity was due to low antibody concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Overall, while AChR L-CBA demonstrates good sensitivity for detecting low concentrations of AChR antibodies, F-CBA performs less reliably in such cases. Since clustered AChR-CBAs can also identify antibodies that are not detectable by RIPA, we recommend that both RIPA and CBA be used together in the routine diagnosis of MG whenever possible. When available, L-CBA should be preferred over F-CBA due to its higher sensitivity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1459423","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:10:16Z","timestamp":1748405416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assay"],"prefix":"10.3389","volume":"16","author":[{"given":"John S.","family":"Tzartos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigli G.","family":"Vakrakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Karagiorgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Zouvelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Chroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Damato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Salakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Sfyroera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Veltsista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Voumvourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10342-3","article-title":"Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age","volume":"268","author":"Monte","year":"2021","journal-title":"J Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"B7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2013A multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577850","article-title":"The clinical need for clustered AChR cell-based assay testing of seronegative MG","volume":"367","author":"Masi","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in 'seronegative' myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur J Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120084","article-title":"Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis","volume":"432","author":"Mirian","year":"2022","journal-title":"J Neurol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and muSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jneuroim.2019.04.001","article-title":"False-positive acetylcholine receptor antibody results in patients without myasthenia","volume":"332","author":"Maddison","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001162","article-title":"Novel cell-based assay for alpha-3 nicotinic receptor antibodies detects antibodies exclusively in autoimmune autonomic ganglionopathy, Neurol","volume":"9","author":"Karagiorgou","year":"2022","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230210","article-title":"Detection of autoantibodies against the acetylcholine receptor, evaluation of commercially available methodologies: fixed cell-based assay, radioimmunoprecipitation assay and enzyme-linked immunosorbent assay","volume":"11","author":"Diogenes","year":"2024","journal-title":"J Neuromuscul Di"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100846","DOI":"10.1016\/j.lanwpc.2023.100846","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study","volume":"38","author":"Li","year":"2023","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1459423\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:10:17Z","timestamp":1748405417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1459423\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1459423"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1459423","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"article-number":"1459423"}}